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1. Introduction 
Tubulocystic carcinoma is a rare renal tumor with distinct characteristics which were 
recently described in details in three large series (1, 2, 3). Tubulocystic carcinomas of the 
kidney well circumscribed tumors. They are usually solitary and are composed of closely 
packed tubules and cysts separated by fibrous stroma and lined by a single layer of cuboidal 
cells with eosinophilic cytoplasm and prominent nucleoli, sometimes with a hobnail 
appearance. These tumors show a low but definite risk of metastasis, and it is therefore 
important to distinguish them from other benign and malignant renal lesions included in 
the differential diagnosis. 
Tubulocystic carcinoma was originally described as a subtype of collecting duct carcinoma 
(4). Carcinoma of the collecting duct of Bellini, first described by Pierre Masson (5) and 
characterized by a tubular or tubulopapillary growth pattern with high grade nuclei, 
follows an aggressive clinical course with a very poor prognosis. When tubulocystic 
carcinoma was first described, it was included in a series of 13 cases called “low grade 
collecting duct carcinoma” (4); these tumors feature a favorable clinical outcome distinct 
from high grade collecting duct carcinoma of the kidney. The entity “low grade collecting 
duct carcinoma” was later divided into two distinct subtypes, mucinous tubular and spindle 
cell carcinoma (6-8) and tubulocystic carcinoma (5). While mucinous tubular and spindle 
cell carcinoma is now recognized as a distinct subtype of renal cell carcinoma (RCC) in the 
World Health Organization classification system of renal tumors (WHO) (3), tubulocystic 
carcinoma is still being characterized (1, 2, 3, 9) and is not yet included in the current WHO 
classification system. Mounting morphologic, biologic, immunohistochemical, and 
molecular evidence supports that this tumor represents a unique subtype of RCC (1, 2, 3). 
2. Clinical presentation and epidemiology 
In the majority of cases, the tumor is discovered incidentally. Less commonly, a patient with 
tubulocystic carcinoma of the kidney may present with nonspecific abdominal pain, a flank 
mass, distention, gross hematuria or unintentional weight loss as in reported cases (1, 4, 9). 
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Tubulocystic carcinoma occurs in the 4th through the 9th decades of life. Patients range in age 
from 30 to 80 years in the 64 reported cases (1, 2, 3, 9), with an overall mean age of 57.2 
years. Tubulocystic carcinoma arises in men in the vast majority of cases, with an overall 
male to female ratio of 7:1. 
3. Gross pathology 
Tubulocystic carcinomas are well circumscribed masses composed of multilocular cystic 
spaces, some containing serous fluid. The cut surface is characteristically described as 
“bubble-wrap”, “spongy” or “Swiss cheese” in appearance due to the multiple cystic spaces. 
The tumors typically do not show areas of solid growth, and hemorrhage or necrosis is 
uncommon. The reported sizes of these tumors have ranged from 0.5 to 17.5cm with an 
overall mean of 4.3cm. The majority of the tumors involve the renal cortex or the cortex and 
medulla (1, 2, 3, 9), not the medulla alone, which would be the typical location of a collecting 
duct carcinoma.  
In the majority of recently studied cases (51 of 64), tubulocystic carcinoma arises as a single 
nodule. Yang et al. reported 5 of 13 cases were associated with papillary renal cell 
neoplasms.  
4. Histology 
The tumors are composed of variably sized, closely packed tubules and cysts separated by 
thin fibrous septae. There is no ovarian-type stroma or desmoplasia in the fibrous septae. 
The cysts typically range from 0.05 to 2mm, but can be as large as 1 cm (1, 3). Areas of 
papillary architecture or solid growth are not identified unless the tumor is associated with 
papillary cell neoplasms. The tubules and cysts are lined by a single layer of cuboidal cells 
with eosinophilic cytoplasm (Figure 1). A hobnail morphology is characteristic. Nucleoli are 
typically prominent, and the majority of cases would be graded as Fuhrman nuclear grade 3. 
Although we typically do not grade tubulocystic carcinoma with Fuhrman grading system 
since this tumor is biologically low grade. Mitoses are rare or absent. Necrosis or 
lymphovascular invasion is usually not identified. 
One of the common findings associated with tubulocystic carcinoma is the coexisting 
papillary renal cell neoplasms. In the previous study, tubulocystic carcinoma was found 
adjacent to and/or intermingled with papillary renal cell carcinoma (RCC) and papillary 
adenoma in 4 of 15 cases, and 1 was found in conjunction with papillary carcinomatosis (3). 
The associated papillary RCC can be type 1 or type 2 (Figure 2). The findings have been 
substantiated with more cases in our experience although other series have not reported 
tubulocystic carcinoma in association with other forms of RCC (1, 2, 4, 9). 
5. Differntial diagnosis 
The differential diagnosis includes simple cortical cyst, cystic nephroma, multilocular cystic 
RCC, and mixed epithelial and stromal tumor of the kidney.   
Simple cortical cysts 
Simple cortical cysts are not multilocular, and the lining cells resemble normal renal tubules.  
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Fig. 1. Tubulocystic carcinoma is composed of cystic structures lined by tumor cells with 
eosinophilic cytoplasm and prominent nucleoli. 
Cystic nephroma 
Cystic nephroma can be multiloculated and lined by a single layer of epithelial cells. The 
lining epithelium is composed of flattened or attenuated cells; there may be hobnailing. 
However, significant nuclear atypia is absent and nucleoli are not prominent. Also cystic 
nephroma may have ovarian-type of stroma.  
Mixed epithelial and stromal tumor 
Mixed epithelial and stromal tumor of the kidney can be distinguished by the presence of 
stromal proliferation in the septae and variable histology of the cyst lining cells, which are 
typically not high nuclear grade. 
Multilocular cystic renal cell carcinoma 
The cysts of multilocular cystic RCC are lined by clear cells similar to clear cell RCC, without 
eosinophilic cytoplasm or high nuclear grade; nests of clear cells are also present in the walls 
of the cysts.  
6. Immunohistochemistry  
Tubulocystic carcinoma is positive for CD10 and AMACR (P504S), and shows weak or 
heterogeneous staining for CK7 (2, 10). Strong staining is seen for CK8, CK18 and CK19 (1, 2, 
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9). It is also positive for Pax2, kidney specific cadherin, carbonic anhydrase IX, and 
parvalbumin (1). There have been mixed reports of the expression of high molecular weight 
cytokeratin and UEA-1 (1, 2, 9, 11). This mixture of expression of proximal and distal 
nephron markers argues against origin from the collecting duct system. Yang et al. have 
proposed that the AMACR and CK7 expression, along with other features (see Gross 
Pathology and Molecular Characteristics) suggests a relationship with papillary RCC. 
 
 
Fig. 2. Co-existing tubulocystic carcinoma (on the left side) and type 2 papillary RCC, high 
grade (on the right side) of the photo. 
7. Ultrastructural features 
Amin et al. report that electron microscopy of tubulocystic carcinoma reveals features of 
both proximal convoluted tubules and intercalated cells of the collecting duct (1). Abundant 
microvilli with brush border organization was reminiscent of proximal convoluted tubules. 
A few cells showed shorter, sparse microvilli with cytoplasmic interdigitation, 
corresponding to intercalated cells. Mitochondria are abundant in tumor cells (1, 9). 
8. Molecular features 
Yang et al. demonstrated a unique molecular signature of tubulocystic carcinoma in 
comparison to other renal tumors (n = 55) and normal renal tissue using gene expression 
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microarray analysis. Clustering analysis of that data revealed tubulocystic carcinoma to be 
closely related to papillary RCC; both types 1 and 2 dimensional clustering placed tubulocystic 
carcinoma between low and high grade papillary RCC. Comparative genomic microarray 
analysis was performed and demonstrated gains of chromosome 17p and 17q (trisomy 17), 
similar to papillary RCC. Gains of chromosome 7p and 7q (trisomy 7), also characteristic of 
papillary RCC, were not identified in the one case of tubulocystic carcinoma studied (3).  
A recent study by Zhou et al on tubulocystic carcinoma and papillary RCC was performed by 
multicolor fluorescence in situ hybridization (FISH) assay containing probes for chromosomes 
7, 17, and Y. Typically papillary RCCs have frequent loss of chromosome Y, and gains of 
chromosomes 7 and 17 (trisomies 7 and 17). Particularly chromosome 17 gain is believed to be 
relatively specific for papillary RCC, as previously reported in 93% to 100% of papillary RCC 
(12). This study by Zhou et al showed that 10/12 (83%) cases of tubulocystic carcinoma had 
chromosome 7 gains, while only 8/12 (66.7%) cases had chromosome 17 gains, and 8/9 cases 
had the Y chromosome loss. The findings suggested a strong genetic similarity between 
tubulocytic carcinoma and papillary RCC. However, they are not identical in the cytogenetic 
changes, since one third of tubulocytic carcinomas cases did not demonstrated typical gains of 
chromosome 17, which are relatively specific for papillary RCC.  
Using gene expression profiling, Amin et al. found differential expression of genes related to 
cell cycle and biomolecule metabolism when compared to clear cell and chromophobe RCC- 
the origin from the collecting duct of Bellini. However, the findings suggest that tubulocytic 
carcinoma is a distinct subtype of renal cell carcinoma, no papillary RCCs were included in 
the comparison (1). 
Recently, Osunkoya et al.compared mRNA expression of several genes in tubulocystic and 
collecting duct carcinomas. The genes were chosen in light of immunohistochemical 
characterization of these tumors (see Immunohistochemistry). Tubulocystic carcinomas showed 
relative overexpression of vimentin, p53 and AMACR. While not statistically significant, 
tubulocystic carcinoma tended to have higher levels of E-cadherin and CD10, and lower levels 
of CK19. CK7 and parvalbumin expression were not different between the two groups 13). 
9. Clinical outcome and prognosis 
The majority of tumors (50/64) have been stage T1 at presentation; 9 were stage T2 and 5 
were T3 (1, 2, 3, 9, 11). Where tumors were discovered antemortem, treatment was with total 
or partial nephrectomy (1, 2, 3, 9 11) . 
Where available, clinical follow-up has ranged from 3 to104 months. The vast majority of 
patients did not experience recurrence or metastasis, and were alive with no evidence of 
disease. MacLennan et al. report one patient who died of widespread intraabdominal 
metastasis 46 months after diagnosis (11). Yang et al. reported one patient with pelvic lymph 
node metastasis at nephrectomy that the metastatic tumor was histologically identical to the 
primary, but no evidence of disease with limited follow-up (3). Other patients in that series 
did show metastatic disease from their concurrent papillary RCC. In the series by Amin et 
al, one patient developed local recurrence and two developed distant metastasis, one to liver 
and both to bone (1). All the patients in the series by Azoulay et al. had no evidence of 
recurrence or metastasis (2). 
Overall, tubulocystic carcinomas have a small but definite risk for metastasis, and are best 
considered a low malignant tumor. This risk is markedly increased when tubulocystic 
carcinoma is associated with high grade papillary RCC. 
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10. Conclusion 
Tubulocystic carcinoma is a rare renal tumor with distinct characteristics. Although 
originally described as a low grade collecting duct carcinoma, the biologic behavior, 
immunohistochemical profile, and molecular signature of these tumors do not support 
origin from the collecting ducts of Bellini, and suggests that they are a distinct subtype of 
renal cell carcinoma, with a close relationship to papillary renal cell carcinoma. This 
relationship has been observed in a subset of tubulocystic carcinoma and needs further 
investigation. These tumors show a low but definite risk of metastasis, and it is therefore 
important to distinguish them from other renal lesions in the differential diagnosis. 
11. References 
[1] Amin MB, MacLennan GT, Gupta R, et al. Tubulocystic carcinoma of the kidney: 
clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell 
carcinoma. Am J Surg Pathol. 2009;33:384-392. 
[2] Azoulay S, Vieillefond A, Paraf F, et al. Tubulocystic carcinoma of the kidney: a new 
entity among renal tumors. Virchows Arch. 2007;451:905-909. 
[3] Yang XJ, Zhou M, Hes O, et al. Tubulocystic carcinoma of the kidney: clinicopathologic 
and molecular characterization. Am J Surg Pathol. 2008;32:177-187. 
[4] MacLennan GT, Farrow GM, Bostwick DG. Low-grade collecting duct carcinoma of the 
kidney: report of 13 cases of low-grade mucinous tubulocystic renal carcinoma of 
possible collecting duct origin. Urology. 1997;50:679-684. 
[5] Masson P. Tumeurs Humaines 1955. Human Tumors, Histology, Diagnosis and Technique. 
Detroit: Wayne State University Press; 1970. 
[6] Parwani AV, Husain AN, Epstein JI, et al. Low-grade myxoid renal epithelial neoplasms 
with distal nephron differentiation. Hum Pathol. 2001;32:506-512. 
[7] Srigley JR, Eble JN, Grignon DJ. Unusual renal cell carcinoma (RCC) with prominent 
spindle cell change possibly related to the loop of Henle. Modern Pathology. 
1999;12:107A. 
[8] Srigley JR, Kapusta L, Reuter V. Phenotypic, molecular, and ultrastructural studies of a 
novel low grade renal epithelial neoplasm possibly related to the loop of Henle. 
Modern Pathology. 2002;15:182A. 
[9] Farah R, Ben-Izhak O, Munichor M, et al. Low-grade renal collecting duct carcinoma. A 
case report with histochemical, immunohistochemical, and ultrastructural study. 
Ann Diagn Pathol. 2005;9:46-48. 
[10] Eble JN SG, Epstein JI. Pathology and Genetics of Tumors of the Urinary System and Male 
Genital Organs. Lyon: IARC Press; 2004. 
[11] MacLennan GT, Bostwick DG. Tubulocystic carcinoma, mucinous tubular and spindle 
cell carcinoma, and other recently described rare renal tumors. Clin Lab Med. 
2005;25:393-416. 
[12] Zhou M, Yang XJ, Lopez J. Renal tubulocystic carcinoma is closely related to papillary 
renal cell carcinoma: implications for pathologic classification. Am J Surg Pathol. 
2009. 
[13] Osunkoya AO, Young AN, Wang W, et al. Comparison of Gene Expression Profiles in 
Tubulocystic Carcinoma and Collecting Duct Carcinoma of the Kidney. Am J Surg 
Pathol. 2009. 
www.intechopen.com
Renal Cell Carcinoma
Edited by Dr. Hendrik Van Poppel
ISBN 978-953-307-844-1
Hard cover, 144 pages
Publisher InTech
Published online 16, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Surgical and medical oncologists have been unable to decrease renal cell carcinoma mortality for uncertain
reasons, although a lot of progress has been made in diagnosis and imaging, recognition of different genetic
and pathological entities, management of localized disease and in the research on new drug treatments for
advanced stages of the disease, potentially combined with surgery. The purpose of this book, which tackles a
number of separate interesting topics, is to provide further insight into the disease and the management of
early and advanced renal cell carcinoma. The volume is divided into different parts; the first part covers the
characterization of renal masses and the second part covers rare distinct pathological entity. In the
management section, active surveillance, partial nephrectomy and radiofrequency ablation are presented. A
separate chapter reviews the management of Von Hippel Lindau disease, and finally, conventional and
aberrant signaling pathways are explored.
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